Gleason grading system


Also found in: Wikipedia.

Gleason grading system

Oncology The most widely used system for stratifying the histologic features of prostate CA, delineated by Gleason, dividing the lesions into 5 groups of ↓ glandular differentiation and worsening prognosis

Gleason grading system

A method of predicting the tendency of a tumor in the prostate to metastasize based on how similar the tumor is to normal prostate tissue.
Mentioned in: Prostate Cancer
References in periodicals archive ?
Clinical risk assessment is primarily determined by pathologic grade based on the Gleason grading system, as initially proposed in the 1960s and modified multiple times thereafter (3).
Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Arch Pathol Lab Med.
On the current Gleason grading system, Gleason patterns 1 and 2 (Gleason score 2-5) have no longer been used in the grading of needle biopsies and only rarely on other specimens.
[9] Nearly after 50 years the Gleason grading system remains novel, in that it is based on the architectural pattern of the tumour alone (Gleason patterns 1-5); the sum of the two most common patterns- that is primary Gleason pattern plus secondary Gleason pattern equals Gleason Score (GS)--conveys the most clinical meaning.
Pathological stage was assessed using 2002 TNM system, and tumor grading was classified using the Gleason grading system (2001-2005) and the revised 2005 Gleason grading system afterwards.
This edition has a new chapter on pathologic conditions of the ureter and renal pelvis; new entities; new renal cell carcinoma subtypes and intraductal carcinoma of the prostate; immunohistochemistry in the diagnosis of major genitourinary diseases and specimen handling, reporting, and staging for all major urologic malignancies; and updates to the International Society of Urological Pathology/Vancouver classification of renal tumors, the Gleason grading system for prostate cancer, and the Fuhrman grading system for renal cell carcinoma.
Klein and colleagues collaborated with Genomic Health, Inc., to develop the Oncotype DX Genomic Prostate Score, designed to be used in conjunction with the Gleason grading system, prostate-specific antigen (PSA) testing, and other clinical parameters to personalize treatment based on the underlying biology of an individual patient's prostate cancer.